This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:starting:physician:reluctant [06.01.2019]
sallieq [Specific research]
home:starting:physician:reluctant [07.19.2019] (current)
sallieq [Specific research]
Line 190: Line 190:
-Benefits of RAS blockade with olmesartan treatment ​are sustained after study discontinued. (({{pubmed>​long:​24772521}})) ​PMID 24772521+Benefits of RAS blockade with olmesartan treatment sustained after study discontinued. PMID 24772521.(({{pubmed>​long:​24772521}})) ​ // ​ Implies that immunopathology may occur unpredictably after discontinuing Olmesartan until microbial infection gets the upper hand again.//
home/starting/physician/reluctant.1559429217.txt.gz · Last modified: 06.01.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.